替比夫定与拉米夫定治疗慢性乙型肝炎疗效观察

目的:探讨替比夫定与拉米夫定治疗慢性乙型肝炎的临床效果.方法:选取慢性乙型肝炎患者82例,随机分为替比夫定组和拉米夫定组,各41例,替比夫定组给予替比夫定治疗,拉米夫定组则给予拉米夫定治疗.分别比较治疗前后2组的乙型肝炎病毒-DNA(HBV-DNA)、乙型肝炎病毒e抗原(HBeAg)、谷草氨基转移酶(AST)、谷丙氨基转移酶(ALT)水平;治疗第12、24、48周比较2组HBV-DNA、HBeAg的转阴率以及AST、ALT的复常率,并对其安全性进行评价.结果:2组患者在治疗后第12、24、48周,HBV-DNA、HBeAg、AST、ALT水平均明显低于治疗前(P<0.01);替比夫定组患者治疗后第48周HBV-DNA的转阴率高于拉米夫定组(P<0.05);替比夫定组患者治疗后第24周和第48周AST、ALT的复常率也均明显高于拉米夫定组(P<0.05).结论:替比夫定治疗慢性乙型肝炎较拉米夫定疗效显著,安全性好,值得临床推广.

Effect observation of telbivudine and lamivudine in the treatment of chronic hepatitis B

Objective:To investigate the effects of telbivudine and lamivudine in the treatment of chronic hepatitis B ( CHB ) . Methods:Eighty-two CHB patients were randomly divided into the telbivudine group and lamivudine group ( 41 cases each group ) . Telbivudine group and lamivudine group were treated with telbivudine and lamivudine,respectively. The levels of HBV-DNA,HBeAg, AST and ALT in two groups between before and after treatment were compared. The rates of negative-inverted of HBV-DNA and HBeAg and recovery rates of AST and ALT in two groups were compared after 12,24 and 48 weeks of treatment,the safety of which was evaluated. Results:After 12, 24 and 48 weeks of treatment, the levels of HBV-DNA, HBeAg, AST and ALT in two groups were significantly lower than before treatment(P <0. 01). After 48 weeks of treatment,the rate of negative-inverted of HBV-DNA in telbivudine group was higher than that in lamivudine group(P<0. 05). After 24 and 48 weeks of treatment,the recovery rates of AST and ALT in telbivudine group were significantly higher than those in lamivudine group(P<0. 05). Conclusions:The treatment of CHB patients with telbivudine is good effect and safety,which is worthy of clinical use.